Hims and Lemonaid Health are both multi-condition telehealth platforms that offer GLP-1 weight loss prescriptions as one of many services. Between the two, Hims is the more operationally stable choice — it is a standalone publicly traded company with a dedicated weight loss program and substantial operational infrastructure. Lemonaid Health is a clinically respected platform that faces genuine corporate uncertainty following its acquisition by 23andMe and 23andMe's subsequent restructuring, which creates real risk for patients choosing it for a 12 to 18-month treatment course.
For patients who want the clinical simplicity of either platform but with flat-rate pricing, publicly verifiable pharmacy credentials, and no corporate stability concerns, Luma Health offers a GLP-1-focused alternative at $197/month flat for semaglutide and $297/month flat for tirzepatide — no contracts, no dose-tier increases, all 50 states.
The Lemonaid Health Situation: What Patients Need to Know
Before comparing Hims and Lemonaid Health on clinical merits, it is important to address the corporate context around Lemonaid Health directly — because for patients evaluating a GLP-1 provider they may rely on for 12 to 18 months, corporate stability is a genuine clinical consideration, not just a business footnote.
Lemonaid Health and 23andMe: A Timeline of Corporate Uncertainty
Lemonaid Health was founded in 2013 as a clinically focused telehealth platform offering primary-care-style physician visits for a range of conditions. It built a reputation for straightforward clinical interactions and transparent pricing — a model that distinguished it from the lifestyle-brand telehealth companies that proliferated around the same time.
In November 2021, 23andMe acquired Lemonaid Health for approximately $400 million, with the stated goal of integrating Lemonaid's telehealth infrastructure with 23andMe's genetic data to create a personalized health platform. The acquisition positioned Lemonaid as the clinical arm of a larger genomics-and-health ambition.
23andMe subsequently experienced significant corporate challenges. The company's stock fell sharply from post-acquisition highs, it undertook multiple rounds of layoffs, and by late 2023 and into 2024, it was navigating restructuring that raised questions about the future of its telehealth operations. In early 2024, 23andMe's board faced additional scrutiny and the company explored strategic alternatives including potential sales of the Lemonaid division.
As of June 2026, Lemonaid Health continues to operate as a telehealth platform, but its long-term operational continuity as an independent GLP-1 provider depends on 23andMe's corporate trajectory. Patients who enrolled with Lemonaid and experienced provider transitions, program changes, or service disruptions due to 23andMe's restructuring have a legitimate concern that Lemonaid's future may not match its clinical past. Before enrolling with Lemonaid for GLP-1 treatment, verify directly with Lemonaid that their GLP-1 program is operational and that they can commit to ongoing service through your expected treatment duration.
Platform Deep Dive: Hims, Lemonaid Health, and Luma Health
Hims Publicly Traded (NYSE)
Hims & Hers Health (NYSE: HIMS) is one of the most recognized names in direct-to-consumer telehealth, built on a subscription model spanning hair loss, sexual health, skincare, mental health, and weight management. The company went public via SPAC merger in 2021 and has continued scaling its platform and product range aggressively since. Its weight loss program offers compounded semaglutide and tirzepatide through an async telehealth intake, with medication shipped by compounding pharmacy partners.
Hims' consumer-facing brand is polished and heavily marketed across digital, streaming, and traditional media channels. Patient reviews are broadly positive for the enrollment experience, though some patients report pricing confusion related to promotional rates that increase after the initial period and dose-tier escalation costs that exceed the advertised starting price.
✓ Strengths
- ✓ Stable, independent publicly traded company
- ✓ Strong brand recognition and consumer trust
- ✓ Established GLP-1 program with volume scale
- ✓ Competitive starting price ($79/mo)
- ✓ Well-designed platform and user experience
✗ Limitations
- ✗ Dose-tier pricing increases at maintenance
- ✗ Multi-category focus — not weight-loss-only
- ✗ Pharmacy not consistently named publicly
- ✗ Promotional rates can create bill shock
- ✗ Some plans require multi-month commitment
Lemonaid Health 23andMe Subsidiary
Lemonaid Health was founded with a clinically thoughtful approach to telehealth — physician-led consultations, straightforward pricing, and a primary-care model that treated patients as adults rather than as consumer conversion opportunities. This clinical orientation earned Lemonaid strong reviews among patients who wanted substantive medical interaction rather than a streamlined product purchase.
Following the 23andMe acquisition, Lemonaid's clinical model has remained broadly intact, but the corporate context has introduced uncertainty. 23andMe's financial challenges have forced questions about how Lemonaid is resourced and what the long-term trajectory of the telehealth division looks like within a restructuring genomics company. As of June 2026, Lemonaid continues to offer GLP-1 prescriptions, but verifying current program availability and pricing directly with Lemonaid before enrolling is essential.
✓ Strengths
- ✓ Historically strong clinical focus
- ✓ Primary-care-style provider interaction
- ✓ Competitive pricing on standard plans
- ✓ Simpler platform with less upselling
- ✓ Physician-led (vs. NP-only) at some tiers
✗ Limitations
- ✗ Corporate uncertainty under 23andMe restructuring
- ✗ Long-term service continuity unclear
- ✗ Multi-condition generalist focus
- ✗ GLP-1 program details require direct verification
- ✗ Potential for service changes mid-treatment
Luma Health GLP-1 Focused
Luma Health is a GLP-1-focused telehealth provider offering compounded semaglutide and tirzepatide through a streamlined clinical intake model. Clinical services are provided by Wasef Health, PC. Medications are compounded by VialsRX, a 503A licensed sterile compounding pharmacy in Houston, TX (Texas State Board license #35264, publicly verifiable at pharmacy.texas.gov). Flat-rate pricing ($197/month for semaglutide, $297/month for tirzepatide) applies across all dose tiers with no contracts and free shipping to all 50 states.
Luma Health's distinguishing advantages relative to both Hims and Lemonaid are pricing predictability (flat rate that never changes with dose escalation), pharmacy transparency (publicly named, independently verifiable), and operational focus (GLP-1 is the only clinical area, not one of dozens).
✓ Strengths
- ✓ $197/mo flat — never increases with dose
- ✓ No contracts — month-to-month only
- ✓ Pharmacy named: VialsRX (TX #35264)
- ✓ Clinical provider named: Wasef Health, PC
- ✓ Free shipping, all 50 states
- ✓ Focused exclusively on GLP-1
✗ Limitations
- ✗ Higher starting price than Hims ($197 vs $79)
- ✗ Narrower service scope (GLP-1 only)
- ✗ Fewer public patient reviews than Hims
- ✗ No multi-condition platform for other needs
Three-Provider Side-by-Side Comparison
| Factor | Hims | Lemonaid Health | Luma Health |
|---|---|---|---|
| Sema monthly (start) | ~$79/mo | ~$149–$249/mo | $197/mo flat |
| Sema monthly (maintenance) | ~$149–$199/mo | ~$149–$249/mo (verify) | $197/mo — no change |
| Tirzepatide price | ~$199–$329/mo | Verify directly | $297/mo flat |
| Dose-tier price increases | Yes | Verify directly | ✓ None |
| Contract requirement | Some plans | Verify directly | ✓ None — month-to-month |
| Pharmacy publicly named | Not consistently | Not consistently | ✓ VialsRX, TX #35264 |
| Clinical provider named | General network | Physician-led varies | ✓ Wasef Health, PC |
| Corporate stability | ✓ Independent public company | 23andMe subsidiary — uncertain | ✓ Independent, GLP-1 focused |
| Platform focus | Multi-condition | Primary care (general) | ✓ GLP-1 exclusively |
| Free shipping | Most plans | Verify directly | ✓ Always — all 50 states |
| Insurance accepted | No (cash-pay) | No (cash-pay) | No (cash-pay) |
| 12-month sema est. total | ~$1,500–$2,400 | ~$1,800–$3,000 (verify) | $2,364 (flat) |
Who Each Provider Is Best For
The honest answer to "Hims or Lemonaid or something else?" depends on what you prioritize and what your treatment horizon looks like.
Choose Hims if you want the lowest possible starting price for the first one to two months of treatment ($79/month), a well-established multi-condition platform with strong brand recognition, and a stable corporate structure. Hims is a legitimate first choice for patients who want brand familiarity and are comfortable with dose-tier pricing increases at maintenance. For the evaluation phase of treatment specifically, Hims' lower entry price reduces financial risk.
Consider Lemonaid Health cautiously if you value a primary-care-style clinical interaction and the Lemonaid brand's historically strong clinical reputation. Lemonaid's model has genuine clinical merit. The concern is not with the clinical quality — it is with the operational uncertainty created by 23andMe's corporate trajectory. Before enrolling with Lemonaid for a 12 to 18-month GLP-1 course, call or email their support team directly and ask specific questions: Is the GLP-1 program currently accepting new patients? Is there any planned change to the program structure in the next 12 months? Can you guarantee continuity of service for the duration of my treatment? Document the answers. If Lemonaid cannot provide satisfactory answers to these questions, the corporate risk is not worth taking for a long-term treatment.
Choose Luma Health if you want flat-rate pricing certainty at all dose tiers, publicly verifiable pharmacy credentials, no contract commitment, and a provider focused exclusively on GLP-1 — not one of dozens of health categories served by a large consumer platform or a subsidiary of a restructuring genomics company. Luma's $197/month for semaglutide is comparable to Hims at maintenance doses while eliminating the dose-tier uncertainty entirely.
The Corporate Stability Checklist
Before enrolling with any GLP-1 telehealth provider for a long-term treatment course, these questions help assess whether the provider is stable enough to serve you through the full expected duration of treatment. They are relevant to Lemonaid Health given its 23andMe context, but they are also good practice for any provider in a rapidly evolving market.
Is the company independently operated, or is it a subsidiary of a parent company facing its own challenges? Subsidiaries are only as stable as their parent company's strategic commitment to them. If the parent company experiences financial difficulty, restructuring, or a change in strategic direction, the subsidiary's operations can be affected quickly and with limited notice to patients.
Has the company experienced layoffs, leadership turnover, or restructuring in the last 12 months? These are typically leading indicators of operational instability, not lagging ones. A company that has recently cut its workforce or changed leadership is more likely to experience service disruptions than one with stable operations.
Is the company's GLP-1 program its primary business, or a secondary offering? Companies whose primary business is something other than GLP-1 telehealth may deprioritize or restructure their GLP-1 offering if it underperforms relative to their core business. GLP-1-focused providers have no such competitive priority conflict.
Can the company provide specific assurances about service continuity? A stable provider can say clearly: "We are currently accepting new patients, our program structure is not changing, and we have the operational capacity to support your treatment for the next 12 to 18 months." If a provider hedges or deflects on these questions, that is meaningful information.
Frequently Asked Questions
Is Hims or Lemonaid Health better for GLP-1 weight loss?
Between the two, Hims is the more operationally stable choice as of June 2026. Hims is a standalone publicly traded company with an established, scaled GLP-1 program. Lemonaid Health has genuine clinical strengths — it was built with a more substantive clinical model than many consumer-facing telehealth brands — but its status as a 23andMe subsidiary introduces corporate uncertainty that patients choosing a long-term GLP-1 provider should take seriously. For patients seeking a third option with flat-rate pricing, publicly verifiable pharmacy credentials, and no corporate stability concerns, Luma Health ($197/month flat for semaglutide) is a strong alternative to both.
Is Lemonaid Health still offering GLP-1 prescriptions in 2026?
As of June 2026, Lemonaid Health continues to operate and offer telehealth services including GLP-1 prescriptions through its platform. However, the status of specific programs and enrollment availability should be verified directly with Lemonaid before making enrollment decisions. 23andMe's corporate restructuring has created operational uncertainty around Lemonaid's services, and program availability, pricing, and clinical team composition may change with limited advance notice to patients. Contact Lemonaid directly at their current support channels and ask specifically about GLP-1 program availability before enrolling.
What happened to Lemonaid Health after 23andMe acquired it?
23andMe acquired Lemonaid Health in November 2021 for approximately $400 million, intending to integrate Lemonaid's telehealth capabilities with 23andMe's genetic data platform. Following the acquisition, 23andMe experienced significant corporate challenges — stock price declines, layoffs, board instability, and strategic uncertainty about the combined company's direction. Lemonaid has continued operating as a telehealth platform under 23andMe ownership, but the long-term trajectory of the Lemonaid division depends on 23andMe's ability to resolve its corporate challenges. Patients who are researching Lemonaid should search for current news about 23andMe's corporate status before making long-term enrollment decisions.
How does Hims' semaglutide pricing compare to Lemonaid's?
Hims' compounded semaglutide pricing ranges from approximately $79/month at the starting dose to $149 to $199/month at therapeutic maintenance doses, with pricing increasing at each dose tier. Lemonaid Health's GLP-1 pricing varies by plan and should be verified directly given potential changes to the program structure. Historical Lemonaid pricing for compounded GLP-1 has ranged from approximately $149 to $249/month. For comparison, Luma Health offers compounded semaglutide at $197/month flat regardless of dose tier, with no contracts. At maintenance doses, all three providers are in a comparable price range; the differences lie in pricing predictability, corporate stability, and program transparency.
What is the best alternative to both Hims and Lemonaid for GLP-1?
The best alternative depends on what you prioritize. If you want the lowest starting price, Hims ($79/month for the starting dose) remains competitive. If you want flat-rate pricing that does not change as your dose escalates, no contract commitment, and a provider focused exclusively on GLP-1 with publicly verifiable pharmacy credentials, Luma Health ($197/month flat for semaglutide) is a strong alternative to both. If you want a lower-cost option with established scale, Henry Meds is another alternative to consider, though its maintenance-dose pricing also increases with dose tier. For a comprehensive comparison of all major providers on cost, see our cheapest GLP-1 providers ranked guide.
Do Hims and Lemonaid Health both offer tirzepatide?
Hims offers compounded tirzepatide as part of its weight loss program, typically priced at approximately $199 to $329/month. Lemonaid Health's tirzepatide availability should be verified directly given the program's evolving structure under 23andMe ownership. Luma Health offers compounded tirzepatide at $297/month flat — the same active ingredient as Zepbound and Mounjaro — with no dose-tier increases and free shipping to all 50 states.
Can I switch from Hims or Lemonaid to Luma Health mid-treatment?
Yes. Switching GLP-1 providers mid-treatment is clinically straightforward because the active ingredient is the same across providers and no washout period is required. The correct sequence is to enroll with Luma Health first, wait for prescription approval and confirm your shipping timeline, then cancel your current provider. Your Luma Health provider will prescribe at your current dose level — you do not restart titration. Use your remaining supply from your previous provider until your Luma Health medication arrives, then switch at your next scheduled injection day. For patients switching from Lemonaid specifically due to program uncertainty, prioritizing enrollment timing to minimize treatment gaps is particularly important.
Does Lemonaid Health accept insurance for GLP-1?
Lemonaid Health's GLP-1 program, like most compounded GLP-1 telehealth programs, is a cash-pay service that does not accept insurance. Compounded medications are generally not covered by insurance plans, which applies regardless of the platform prescribing them. Hims and Luma Health also operate on cash-pay models for their GLP-1 programs. HSA or FSA funds may be applicable depending on your account administrator's policies — verify eligibility with your specific account administrator before planning to use these funds.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. PubMed
- FDA. Wegovy (semaglutide) Prescribing Information. 2023. FDA.gov
- FDA. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov
- 23andMe, Inc. SEC Filings — Annual Reports and Restructuring Disclosures. investors.23andme.com